CTLA4-Ig Effectively Controls Clinical Deterioration and Immune Condition in a Murine Model of Foxp3 Deficiency.

Margaux GerbauxEvelyne RoosMathijs WillemsenFrederik StaelsJulika NeumannLeoni BückenJeason HaughtonLidia YshiiJames DooleySusan SchlennerStephanie Humblet-BaronAdrian Liston

Published in: Journal of clinical immunology (2023)

These results highlight the mechanistic diversity of pathogenic pathways initiated by regulatory T cell loss and suggest CTLA4-Ig as a potentially superior therapeutic option for FOXP3-deficient patients.

Keyphrases

regulatory t cells
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
transcription factor
replacement therapy